Trevi Therapeutics plans two pivotal phase III trials for IPF-related chronic cough as FDA alignment achieved (NASDAQ:TRVI)
Trevi TherapeuticsTrevi Therapeutics(US:TRVI) Seeking Alpha·2026-03-18 07:03

Management View - Trevi Therapeutics reported that 2025 was a significant inflection point for growth, driven by positive data readouts from the CORAL trial in patients with idiopathic pulmonary fibrosis (IPF) [2]

Trevi Therapeutics plans two pivotal phase III trials for IPF-related chronic cough as FDA alignment achieved (NASDAQ:TRVI) - Reportify